Results Fifty two patients completed the BCKQ questionnaire: 36 conventional PR programme [20 male, MRC 3 (IQR 2-4), age 67 (±8.5) years, BMI 30 (±6.6) kg/m 2 , FEV 1 (% predicted) 53 (±21), pre ISWT 280 m (±163), pre HADS anxiety 6.6 (±4.8). pre PRAISE 45 (±8.4)] and 16 online [14 male, MRC 3 (IQR 2-4), age 67 (±7.4) years, BMI 25 (±5.0) kg/m 2 , FEV 1 (% predicted) 47 (±27), pre ISWT 365 m (±201), pre HADS anxiety 7.5 (±5.1),pre PRAISE 49 (±7.9)]. There were no significant differences in baseline characteristics. A statistically significant difference was seen in knowledge within each group following either the conventional PR programme (change=5 points, p£0.001) or the web programme (change=11 points, p£0.001). The change in scores between the groups was also significantly different (p£0.01) in favour of the web-based programme (Table 1) . Discussion Patients are able to gain improvements in knowledge around their condition using a website programme as an alternative to the traditional spoken sessions in a PR programme. Rationale Severe corticosteroid refractory asthma is a significant unmet medical need. It accounts for 10% of the asthma population and 50% of the health economic burden. Recent understanding of asthma heterogeneity has evolved beyond clinical characteristics, allowing definition of distinct disease phenotypes such as those defined by levels of Type 2 inflammation (Type-2 high 'eosinophilic' disease and Type-2 low 'neutrophilic' disease). However, a recent study using dupilumab (an antibody that blocks the common IL-4 and IL-13 receptor chain, IL-4Ra) as an add-on therapy in adults with uncontrolled persistent asthma showed efficacy irrespective of baseline eosinophil count (Wenzel et al, Lancet 2016 ). The aim of this work was to use IL-13 transgenic mice to test the hypothesis that a subset of IL-13 mediated airway responses are corticosteroid-unresponsive and contribute to ongoing airways symptoms. Methods IL-13 expression in the lungs was induced using Doxycycline (DOX) in Ccsp-rtTA/Otet-Il-13 double-transgenic (Ccsp/Il-13) mice. Littermate control single transgenic mice also received DOX. Where indicated, mice received daily intra-peritoneal injections of 3 mg/kg Dexamethasone (Dex) for 3-7 days and control mice received saline. Methacholine challenge and lung function measurements were performed and lungs harvested for mRNA analysis and immunohistochemistry (IHC). BALF was obtained for ELISA and differential cell counts. Results Compared to controls, Ccsp/Il-13 mice showed significantly increased airway hyperresponsiveness (AHR) to methacholine and IHC revealed increased bronchial smooth muscle and goblet cell metaplasia. The BALF of these mice contained mixed eosinophilic and neutrophilic inflammation, but neutrophils predominated. Characteristic Th2-responsive genes (Il-13, Eotaxin, Muc5ac, Periostin and SerpinB2) as well as genes more characteristic of Th17 responses (Cxcl1/Kc, Cxcl2 and Csf3) were significantly elevated. Treatment with Dex did not abrogate AHR, even though eosinophilia and the 'Th2' gene signature were significantly reduced. However, neutrophils and the 'Th17' signature remained elevated. Conclusion Although IL-13 promotes eosinophilic airways disease, it can also drive corticosteroid refractory inflammation characterised by persistent neutrophilia, Th17 cytokines and maintenance of AHR. These findings may help explain the beneficial effect of dupilumab in uncontrolled asthma. The Ccsp/Il-13 mouse may be a useful model for dissecting the molecular pathways and mechanisms associated with predominant neutrophilic, corticosteroid refractory disease. -2017-210983.92 TGFß is a widely distributed, pleiotropic cytokine implicated in tissue remodelling in many diseases including severe asthma. It is secreted in a latent form that requires activation for function. Mechanotransduction of intracellular forces through cell surface integrins can lead to TGFß activation. We have previously shown that human airway smooth muscle (HASM) cells can activate TGFb via avb5 integrins. In the present study we have investigated the effect of extracellular matrix (ECM) on basal TGFb activation in primary asthmatic and non-asthmatic HASM cells. We assessed basal TGFb activation in non-asthmatic (n=9) and asthmatic (n=7) HASM cells. TGFb activation was assessed using a TGFb reporter cell assay and a phosphorylated Smad2 ELISA. Cell contractility was assessed using a collagen gel contraction assay and traction force microscopy. ECM was isolated from HASM cells and crossover experiments performed where non-asthmatic cells were cultured on asthmatic ECM and vice-versa then TGFb activity determined. Expression of ECM crosslinking enzymes was
, FEV 1 (% predicted) 47 (±27), pre ISWT 365 m (±201), pre HADS anxiety 7.5 (±5.1),pre PRAISE 49 (±7.9)]. There were no significant differences in baseline characteristics. A statistically significant difference was seen in knowledge within each group following either the conventional PR programme (change=5 points, p£0.001) or the web programme (change=11 points, p£0.001). The change in scores between the groups was also significantly different (p£0.01) in favour of the web-based programme (Table 1) . Discussion Patients are able to gain improvements in knowledge around their condition using a website programme as an alternative to the traditional spoken sessions in a PR programme. Rationale Severe corticosteroid refractory asthma is a significant unmet medical need. It accounts for 10% of the asthma population and 50% of the health economic burden. Recent understanding of asthma heterogeneity has evolved beyond clinical characteristics, allowing definition of distinct disease phenotypes such as those defined by levels of Type 2 inflammation (Type-2 high 'eosinophilic' disease and Type-2 low 'neutrophilic' disease). However, a recent study using dupilumab (an antibody that blocks the common IL-4 and IL-13 receptor chain, IL-4Ra) as an add-on therapy in adults with uncontrolled persistent asthma showed efficacy irrespective of baseline eosinophil count (Wenzel et al, Lancet 2016 ). The aim of this work was to use IL-13 transgenic mice to test the hypothesis that a subset of IL-13 mediated airway responses are corticosteroid-unresponsive and contribute to ongoing airways symptoms. Methods IL-13 expression in the lungs was induced using Doxycycline (DOX) in Ccsp-rtTA/Otet-Il-13 double-transgenic (Ccsp/Il-13) mice. Littermate control single transgenic mice also received DOX. Where indicated, mice received daily intra-peritoneal injections of 3 mg/kg Dexamethasone (Dex) for 3-7 days and control mice received saline. Methacholine challenge and lung function measurements were performed and lungs harvested for mRNA analysis and immunohistochemistry (IHC). BALF was obtained for ELISA and differential cell counts. Results Compared to controls, Ccsp/Il-13 mice showed significantly increased airway hyperresponsiveness (AHR) to methacholine and IHC revealed increased bronchial smooth muscle and goblet cell metaplasia. The BALF of these mice contained mixed eosinophilic and neutrophilic inflammation, but neutrophils predominated. Characteristic Th2-responsive genes (Il-13, Eotaxin, Muc5ac, Periostin and SerpinB2) as well as genes more characteristic of Th17 responses (Cxcl1/Kc, Cxcl2 and Csf3) were significantly elevated. Treatment with Dex did not abrogate AHR, even though eosinophilia and the 'Th2' gene signature were significantly reduced. However, neutrophils and the 'Th17' signature remained elevated. Conclusion Although IL-13 promotes eosinophilic airways disease, it can also drive corticosteroid refractory inflammation characterised by persistent neutrophilia, Th17 cytokines and maintenance of AHR. These findings may help explain the beneficial effect of dupilumab in uncontrolled asthma. The Ccsp/Il-13 mouse may be a useful model for dissecting the molecular pathways and mechanisms associated with predominant neutrophilic, corticosteroid refractory disease. -2017-210983.92 TGFß is a widely distributed, pleiotropic cytokine implicated in tissue remodelling in many diseases including severe asthma. It is secreted in a latent form that requires activation for function. Mechanotransduction of intracellular forces through cell surface integrins can lead to TGFß activation. We have previously shown that human airway smooth muscle (HASM) cells can activate TGFb via avb5 integrins. In the present study we have investigated the effect of extracellular matrix (ECM) on basal TGFb activation in primary asthmatic and non-asthmatic HASM cells. We assessed basal TGFb activation in non-asthmatic (n=9) and asthmatic (n=7) HASM cells. TGFb activation was assessed using a TGFb reporter cell assay and a phosphorylated Smad2 ELISA. Cell contractility was assessed using a collagen gel contraction assay and traction force microscopy. ECM was isolated from HASM cells and crossover experiments performed where non-asthmatic cells were cultured on asthmatic ECM and vice-versa then TGFb activity determined. Expression of ECM crosslinking enzymes was
REFERENCE

Spoken sessions
Thorax 2017;72(Suppl 3):A1-278 A53
